Following President Trump’s directive to accelerate medical treatments for serious mental illnesses, FDA announced major steps to support the development of serotonin-2A agonists & related products—a class of medications historically referred to as "psychedelic" drugs.
National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder)
National priority voucher for methylone (for post-traumatic stress disorder)
First-ever noribogaine study authorized for alcohol use disorder
Advancing guidance for sponsors developing these products
Learn more: https://www.fda.gov/news-events/pre...ious-mental-illness-following-executive-order
Mike
National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder) National priority voucher for methylone (for post-traumatic stress disorder) First-ever noribogaine study authorized for alcohol use disorder Advancing guidance for sponsors developing these productsLearn more: https://www.fda.gov/news-events/pre...ious-mental-illness-following-executive-order
Mike
️BREAKING: U.S President Trump CANCELS Jared Kushner and Steve Witkoff’s trip to Pakistan for negotiations with Iran:
